neurocare group AG

🔔 New Episode Out Now! 🎙️   In this latest interview, Dr Phern Chern Tor Psychiatrist and Head of Neurostimulation services at the Institute of Mental Health in Singapore, joins Dr. Trevor Brown to explore the key elements of running a successful TMS service.   Dr. Tor shares his insights on managing adverse events, assessing pain tolerance, and evaluating patient suitability to ensure safety and successful outcomes. He also highlights the economic advantages of TMS in a cost-effective, stepped-care model for treatment-resistant depression.   A central focus of the conversation is the importance of the therapeutic relationship, and how starting treatment gradually can improve patient comfort and results.   Tune in for expert advice on optimizing TMS services! See the link to the video in the comments below 👇   #TMS #rTMS #MagneticStimulation #TranscranialMagneticStimlation #Neurostimulation #ClinicalCare #Psychiatry #Nursing #Psychology #MentalHealth #TMSClinic #DepressionTreatment #HealthcareProfessionals #ProfessionalSupervision #PatientDoctorRelationship #TherapeuticRelationship

🌍 Today, on World Mental Health Day 2024, we focus on the theme of Workplace Mental Health—a topic that has never been more critical. Mental health services received a record-breaking 5 million referrals in 2023, a 33% increase from 2019. And in workplaces, 17% of employees are expected to struggle with a diagnosed mental health condition this year, with an additional 38% suffering without a formal diagnosis.   While 81% of workplaces have increased their focus on mental health since the pandemic, 1 in 3 employees still feel that support is inadequate. This is where innovation in mental health care becomes essential, both in the workplace and beyond.   At neurocare, neuroplasticity is anchoring our Best Practice Platform. Neuroplasticity is our brain’s natural ability to learn and adapt and is the new paradigm in mental health and performance.  We help clinicians do an intake analysis of the brain and sleep using common psychology questionnaires. Then, based on that intake data, we integrate talk therapy with neuromodulation or other tools chosen by the clinicians, empowering them to offer their patients personalized therapy. For professionals, our platform provides all the tools that empower clinicians, such as TMS, Neurofeedback, QEEG, and related training, to choose protocols or improve sleep and neurobiology. For patients, that means personalized therapy with longer-lasting and faster outcomes addressing the underlying causes of mental illness and improving their self-regulation instead of the one-size-fits-all treatment of symptoms. This World Mental Health Day, let’s continue to advocate for mental health in the workplace and beyond, and work towards solutions that are not only effective but truly transformative. Together, we can create healthier workplaces—and healthier minds. 💡 #WorldMentalHealthDay #WorkplaceWellbeing #Neuromodulation #TMS #MentalHealthAwareness #EmployeeWellbeing #BrainHealth

We have a new episode out today in Dr. Trevor Brown's Interview Series for neurocare academy! 🎓 〰 Neurofeedback and EEG diagnostic microstates for ADHD, PTSD, and Schizophrenia with Dr. Tomas Ros 〰 Dr. Tomas Ros is a neuroscientist and EEG researcher at the Center for Biomedical Imaging at the University of Geneva in Switzerland. In this interview, he shares his groundbreaking insights into the use of #neurofeedback and #EEG microstates in diagnosing and treating various mental health disorders. Learn more about how neurofeedback protocols can be personalized to enhance treatment effectiveness for conditions like #ADHD or #schizophrenia and pioneering approaches to restore alpha brainwave activity in #PTSD patients. 🧠 This is a fascinating discussion for #neurofeedback practitioners or anyone interested in learning more about these conditions and the underlying mechanisms of the brain which can harnessed through these innovative and evidence-based techniques. 🔗 See the link in the comments to watch the full interview. #neurocare #neurocaregroup #neurofeedback #eeg #adhd #ptsd #schizophrenia #psychiatry #psychology #healthcareinnovation #mentalhealth

🚀 neurocare Receives FDA Clearance for Industry-Leading iTBS Protocol for TMS in Depression Treatment 🚀 We're pleased to announce that neurocare's industry-leading intermittent Theta Burst Stimulation (iTBS) protocol has received FDA clearance its industry-leading intermittent Theta Burst Stimulation (iTBS) protocol, available across its Apollo TMS Therapy System and other Transcranial Magnetic Stimulation systems for clinical practice. In recent years, neurocare and its TMS team in Germany have engineered an advanced technology for delivering iTBS, ensuring a consistent and efficient delivery of full stimulation power across the entire burst sequence. This offers a superior solution to other TMS systems on the market, where the pulse strength can decay with subsequent pulses, resulting in less than optimal clinical care. When being treated with an iTBS protocol on the Apollo TMS system, a patient can now receive a reliable stimulation dose that accurately reflects the parameters set by the physician. “We are excited to be able to offer this new best-in-class technology so our customers can in turn provide the best care to their patients,” said Stanford Miller, Group Executive Vice President, and Managing Director of neurocare group North American operations. “We knew it was important to give physicians the confidence in using innovative technologies like TMS, so it was a key focus area for our team to find a solution to the challenge of output power consistency in iTBS stimulation," said Dr Kerstin Häringer, Group Head of TMS technology at neurocare group, Munich, Germany. "Thanks to the dedication of our world-class engineering team, we achieved superior power consistency for our TMS systems, thereby making the iTBS protocol more reliable.” Since 2021, neurocare has built a substantial network of clinic partnerships and private physician users in the field of psychiatry across the USA. More than 175 clinics and institutions have adopted the Apollo TMS Therapy system to help the most difficult-to-treat patients they service. The Apollo is FDA-cleared as a treatment for major depression after a patient has tried and not benefited from oral antidepressant medications. Apollo TMS Therapy is a covered service by most private and public health insurance providers. 🔗 Read the full press release linked in the comments. #neurocare #neurocaregroup #MentalHealthInnovation #TMS #FDAclearance #iTBS #DepressionTreatment #HealthcareTech #HealthcareInnovation #Neurostimulation #Neuromodulation #Psychiatry

📰 A new study suggests #TMS as a treatment for #Depression, is likely to be more beneficial than trying a new antidepressant medication 💊 A recent study published in the #AmericanJournalofPsychiatry highlights a significant advancement in depression treatment: Transcranial Magnetic Stimulation (TMS) therapy may be more effective than trying another course of antidepressant medications, especially after multiple failed attempts. With nearly 300 million people worldwide battling severe depression, this finding offers a promising alternative for those who haven't found relief with traditional treatments. The study, co-authored by Dr. Iris van Oostrom from neurocare Clinics Nederland , found that patients receiving TMS experienced significantly greater reductions in depression symptoms compared to those trialing another course of antidepressant. "After 8 weeks of treatment, we found that the group that received TMS had significantly lower depression rates than the group that received medication during these 8 weeks," says Dr. van Oostrom. As TMS gains recognition in depression treatment guidelines around the world, this non-invasive therapy is becoming a beacon of hope, providing patients with more effective and personalized treatment options. 🔗 Read the full article in the link in the comments. #neurocare #neurocaregroup #bestpractice #psychiatry #psychology #antidepressants #rtms #tms #neurostimulation #neuromodulation #magneticstimulation #depressiontreatment #clinicalcare #healthcareinnovation

🧠 Celebrating a Century of EEG: From Hans Berger's Discovery to Modern Breakthroughs in Mental Health 🧠 For the past 100 years, EEG technology has revolutionized our understanding of the brain, offering invaluable insights in both research and clinical practice. From its origins with Hans Berger's first recordings in 1924 to its present-day applications in psychiatry and neurology, EEG has evolved significantly. At neurocare, we are proud to continue this legacy, advancing QEEG and Neurofeedback to empower clinicians with cutting-edge tools for personalized mental health care. Explore how EEG is shaping the future of psychiatry and psychology. In this article, we speak with neurocare's in-house EEG and Neurofeedback experts Klaus Schellhorn, Trevor Brown, Amna Ghani, and Hartmut Heinrich, who share their insights in the field. 🔗 See the link in the comments to read the article. #neurocare #neurocaregroup #Neuroscience #MentalHealth #Innovation #EEG #Neurofeedback 

🚀 Today we make an important announcement. We are very pleased to welcome Tristan de Boysson as Chairman as well as Prof. Dr. Heinrich von Pierer as a Member of the Supervisory Board for neurocare group AG. Mr. de Boysson brings over 25 years of expertise in investing and corporate leadership. He is currently a Managing Partner at TVM Capital Healthcare, a growth capital healthcare-focused private equity firm headquartered in Dubai and Singapore. His previous experience includes serving as the CEO of Amanat Holdings PJSC, the largest listed healthcare and education investment company in the MENA region. Prof. Dr. Heinrich von Pierer brings his considerable global leadership experience and network to neurocare. Beginning his career at Siemens AG in 1969, Prof. Dr. von Pierer advanced to the position of CEO of the global Siemens Group, serving from 1992 to 2005 and leading businesses in engineering, power generation, healthcare, telecommunications, and finance. Subsequently, he served as Siemens’ Chairman of the Supervisory Board. Our Founder & CEO, Tom Mechtersheimer, said, “the neurocare team is grateful to have the expertise of Mr. de Boysson and Prof. Dr. Heinrich von Pierer on our Supervisory Board. Personally, I am much looking forward to driving neurocare with Tristan de Boysson as our Chairman and am humbled to have access to the immense global business and leadership experience of Prof. Dr. von Pierer. This year marks exciting progress in terms of our new global leadership team recently announced, as well as our new supervisory board and funding which will position neurocare as a global leader in mental health.” Complete statements and details can be found in the press release linked here. #neurocare #neurocaregroup #leadership #boardannouncement #corporategovernance #businessgrowth #strategicleadership #businessleadership #executiveleadership https://lnkd.in/eiui4v99

🚀 Celebrating our Latest Software Milestone for our Digital Therapy Platform! 🎉 We recently came together with our incredible partners and friends at Twip Impact Ventures, QAware GmbH and MaibornWolff GmbH to celebrate the close of a major development sprint for our Digital Therapy Platform Software. neurocare’s DTP software team presented an exciting first look at the new features and tools to help optimize processes for clinicians using neurocare’s innovative neuromodulation techniques. 👏  A big thank you to everyone who supported and helped bring the project to this exciting phase. Your teamwork and collaboration have been first class: Alexander Seipel, Amna Ghani, Bernd Schlüter, Bianca Koch, Christopher Voit, Ethan Rich, Florian Mallmann, Dr. Ghazaleh Erfanianfar, Heiko Deppler, Jakob Schuster, Johannes Geiger, Dr. Katrin Kallweit, Matthias Moosburger, Michael Adersberger, Sahib Jan, Thomas Kothmayr, Tobias D., Yuliya Hasanov Thank you to everyone who helped to organize our get-together a big shout out to MaibornWolff GmbH for providing the wonderful event location.  #neurocare #neurocaregroup #DigitalTherapyPlatform #HealthcareInnovation #TwipImpactVentures #TeamSpirit #MilestoneAchieved #Munich #Impact

Exciting news today as we announce joining forces with Smart TMS, a leading TMS provider with nine clinics across the UK and Ireland! 🙌🌍 This acquisition not only marks an expansion of neurocare's clinic network but it allows the clinics to offer more personalized therapy using neurocare’s unique Digital Therapy Platform (DTP). Founded in 2015, Smart TMS was among the first to offer this neuromodulation technique in patient care in the United Kingdom and has since established several reimbursement agreements with private health insurance companies. Dr. Leah A. Neal, Founder, Psychiatrist, and Medical Director of Smart TMS says: “We look forward to joining forces with neurocare to expand and improve deliverability of TMS and other innovative mental health treatments across the UK. Our team will benefit from sharing expertise with a global network, as well as having access to resources and tools to serve more patients effectively.” Norman Erhard, Senior Vice President of neurocare in Europe, says: “We are thrilled to join forces with Smart TMS, a company with an established network of TMS clinics in the UK and Ireland as well as a team of experienced and renowned professionals in psychiatry and psychology. Collaborating with Smart TMS, we will integrate our Digital Therapy Platform into existing UK clinics. By combining tools like sleep assessment, therapeutics, psychotherapy, neurofeedback, and also neuromodulation technologies such as TMS we are streamlining processes to enhance the individualization of mental healthcare. Our global neurocare network is looking forward to building closer ties with like-minded clinicians and adding value from our established expertise." Read the full Press Release here 🔗 https://lnkd.in/eMfCxPtA #tms #transcranialmagneticstimulation #rtms #neuromodulation #neurostimulation #personalizedmedicine #digitaltherapyplatform #neurocare #neurocaregroup #smarttms #mentalhealth #mentalhealthmatters

🚀 There’s a new episode in our interview series with Dr. Trevor Brown! 🚀 In our latest YouTube release, Trevor interviews TMS expert Dr. Jonathan Downar, Associate Professor of Psychiatry at the University of Toronto. Dr. Downar delves into the neural mechanisms underlying resilience, survival, and their connection to effective depression treatments like Transcranial Magnetic Stimulation (TMS). 🧠 This insightful conversation is valuable for healthcare professionals seeking to understand TMS's practical implications and the neural circuitry of resilience, and for patients wanting to learn how TMS therapy complements these innate mechanisms of the brain. 👉 Watch the full interview here and be sure to subscribe to our channel: https://lnkd.in/eQqQScjS #mentalhealth #TMS #neurocare #psychiatry #neuroscience #depressiontreatment #podcast #healthcareinnovation